- Home
- BRY vs RPID Comparison
BRY vs RPID Comparison
Compare BRY & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- RPID
- Stock Information
- Founded
- BRY 1909
- RPID 2006
- Country
- BRY United States
- RPID United States
- Employees
- BRY N/A
- RPID N/A
- Industry
- BRY Oil & Gas Production
- RPID Medical Specialities
- Sector
- BRY Energy
- RPID Health Care
- Exchange
- BRY Nasdaq
- RPID Nasdaq
- Market Cap
- BRY 186.1M
- RPID 155.6M
- IPO Year
- BRY N/A
- RPID 2021
- Fundamental
- Price
- BRY $3.30
- RPID $3.32
- Analyst Decision
- BRY Buy
- RPID Buy
- Analyst Count
- BRY 2
- RPID 1
- Target Price
- BRY $5.00
- RPID $8.00
- AVG Volume (30 Days)
- BRY 1.3M
- RPID 94.0K
- Earning Date
- BRY 08-08-2025
- RPID 08-01-2025
- Dividend Yield
- BRY 3.64%
- RPID N/A
- EPS Growth
- BRY N/A
- RPID N/A
- EPS
- BRY N/A
- RPID N/A
- Revenue
- BRY $753,737,000.00
- RPID $29,645,000.00
- Revenue This Year
- BRY N/A
- RPID $18.54
- Revenue Next Year
- BRY $0.96
- RPID $20.55
- P/E Ratio
- BRY N/A
- RPID N/A
- Revenue Growth
- BRY N/A
- RPID 28.36
- 52 Week Low
- BRY $2.11
- RPID $0.58
- 52 Week High
- BRY $7.02
- RPID $4.04
- Technical
- Relative Strength Index (RSI)
- BRY 70.73
- RPID 50.47
- Support Level
- BRY $2.99
- RPID $3.00
- Resistance Level
- BRY $3.39
- RPID $3.73
- Average True Range (ATR)
- BRY 0.16
- RPID 0.25
- MACD
- BRY 0.08
- RPID -0.07
- Stochastic Oscillator
- BRY 90.91
- RPID 40.51
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.